![]() |
BioSante completes patient enrollment in LibiGel Phase III trial for treatment of FSD
BioSante Pharmaceuticals, Inc. today announced that enrollment of subjects in the first of two pivotal Phase III LibiGel safety and efficacy trials has been completed.
More... |
| All times are GMT -7. The time now is 12:13 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021